JP2024026255A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024026255A5 JP2024026255A5 JP2023204313A JP2023204313A JP2024026255A5 JP 2024026255 A5 JP2024026255 A5 JP 2024026255A5 JP 2023204313 A JP2023204313 A JP 2023204313A JP 2023204313 A JP2023204313 A JP 2023204313A JP 2024026255 A5 JP2024026255 A5 JP 2024026255A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid position
- domain
- tyrosine
- binding polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025179195A JP2026021377A (ja) | 2018-01-26 | 2025-10-24 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622468P | 2018-01-26 | 2018-01-26 | |
| US62/622,468 | 2018-01-26 | ||
| PCT/US2019/015204 WO2019147973A1 (en) | 2018-01-26 | 2019-01-25 | Fc variants with enhanced binding to fcrn and prolonged half-life |
| JP2020561607A JP7399880B2 (ja) | 2018-01-26 | 2019-01-25 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561607A Division JP7399880B2 (ja) | 2018-01-26 | 2019-01-25 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025179195A Division JP2026021377A (ja) | 2018-01-26 | 2025-10-24 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024026255A JP2024026255A (ja) | 2024-02-28 |
| JP2024026255A5 true JP2024026255A5 (enExample) | 2024-09-05 |
Family
ID=65520379
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561607A Active JP7399880B2 (ja) | 2018-01-26 | 2019-01-25 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
| JP2023204313A Pending JP2024026255A (ja) | 2018-01-26 | 2023-12-04 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
| JP2025179195A Pending JP2026021377A (ja) | 2018-01-26 | 2025-10-24 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561607A Active JP7399880B2 (ja) | 2018-01-26 | 2019-01-25 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025179195A Pending JP2026021377A (ja) | 2018-01-26 | 2025-10-24 | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190263934A1 (enExample) |
| EP (1) | EP3743441A1 (enExample) |
| JP (3) | JP7399880B2 (enExample) |
| KR (2) | KR20250008975A (enExample) |
| CN (2) | CN119350481A (enExample) |
| AU (2) | AU2019212638B2 (enExample) |
| BR (1) | BR112020015006A2 (enExample) |
| CA (1) | CA3089602A1 (enExample) |
| CO (1) | CO2020010269A2 (enExample) |
| IL (2) | IL276286B2 (enExample) |
| MX (2) | MX2020007882A (enExample) |
| MY (1) | MY203898A (enExample) |
| PH (1) | PH12020551134A1 (enExample) |
| SG (1) | SG11202006905YA (enExample) |
| TW (1) | TW201940512A (enExample) |
| WO (1) | WO2019147973A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL276286B2 (en) * | 2018-01-26 | 2025-07-01 | Genzyme Corp | FC variants with improved binding to FCRN and extended half-life |
| TW202120539A (zh) * | 2019-07-25 | 2021-06-01 | 美商健臻公司 | 以FcRn拮抗劑治療抗體媒介之病症的方法 |
| AU2020358854A1 (en) | 2019-10-03 | 2022-05-26 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
| CA3178123A1 (en) * | 2020-05-11 | 2021-11-18 | William Brondyk | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| EP4204091A2 (en) * | 2020-10-29 | 2023-07-05 | Formycon AG | Ace2 fusion proteins and uses thereof |
| EP4347640A1 (en) | 2021-05-27 | 2024-04-10 | Sanofi | Fc variant with enhanced affinity to fc receptors and improved thermal stability |
| JP2024531346A (ja) | 2021-08-20 | 2024-08-29 | インターベット インターナショナル ベー． フェー． | 半減期が延長された抗体およびＩｇＧ融合タンパク質 |
| WO2023244276A2 (en) * | 2021-10-13 | 2023-12-21 | The Wistar Institute Of Anatomy And Biology | DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS |
| TW202413419A (zh) | 2022-05-27 | 2024-04-01 | 法商賽諾菲公司 | 與ｎｋｐ４６和ｂｃｍａ變體結合之具有ｆｃ工程化的自然殺手（ｎｋ）細胞接合物 |
| CN116162171B (zh) * | 2022-10-13 | 2025-06-03 | 深圳市百士通科技开发有限公司 | 抗体突变方法在治疗性抗体药物中的应用 |
| EP4608859A1 (en) | 2022-10-25 | 2025-09-03 | Ablynx N.V. | Glycoengineered fc variant polypeptides with enhanced effector function |
| KR20250120344A (ko) | 2022-12-05 | 2025-08-08 | 사노피 | 트랜스페린 수용체 결합 단백질 |
| WO2025088546A1 (en) | 2023-10-25 | 2025-05-01 | Ablynx N.V. | Fc domain variants with enhanced fc receptor binding |
| WO2025101094A1 (en) * | 2023-11-08 | 2025-05-15 | Ооо «Geropharm» | Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates |
| WO2025149633A1 (en) | 2024-01-12 | 2025-07-17 | Laigo Bio B.V. | Bispecific antigen binding proteins |
| WO2026022712A1 (en) | 2024-07-23 | 2026-01-29 | Sanofi | Cereblon ligase modulator and bcma nk cell engager combination therapy |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| KR101077001B1 (ko) * | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| AU2001270609A1 (en) | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
| US20060067930A1 (en) * | 2004-08-19 | 2006-03-30 | Genentech, Inc. | Polypeptide variants with altered effector function |
| DK1817340T3 (da) | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8163881B2 (en) * | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US8775090B2 (en) * | 2008-12-12 | 2014-07-08 | Medimmune, Llc | Crystals and structure of a human IgG Fc variant with enhanced FcRn binding |
| JP5944831B2 (ja) * | 2009-12-23 | 2016-07-05 | シュニムネ ゲーエムベーハーＳＹＮＩＭＭＵＮＥ ＧｍｂＨ | 抗ｆｌｔ３抗体及びその使用方法 |
| WO2011089211A1 (en) * | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
| TWI588156B (zh) | 2011-03-28 | 2017-06-21 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| US20160068613A1 (en) * | 2013-04-29 | 2016-03-10 | Hoffmann-La Roche Inc. | Fc-receptor binding modified asymmetric antibodies and methods of use |
| SI3215528T1 (sl) * | 2014-11-06 | 2019-11-29 | Hoffmann La Roche | Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe |
| AU2015345320A1 (en) | 2014-11-10 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-IL-1beta antibodies and methods of use |
| KR20250036943A (ko) * | 2016-08-02 | 2025-03-14 | 비스테라, 인크. | 조작된 폴리펩티드 및 그의 용도 |
| IL276286B2 (en) * | 2018-01-26 | 2025-07-01 | Genzyme Corp | FC variants with improved binding to FCRN and extended half-life |
-
2019
- 2019-01-25 IL IL276286A patent/IL276286B2/en unknown
- 2019-01-25 WO PCT/US2019/015204 patent/WO2019147973A1/en not_active Ceased
- 2019-01-25 KR KR1020247043107A patent/KR20250008975A/ko active Pending
- 2019-01-25 BR BR112020015006-1A patent/BR112020015006A2/pt unknown
- 2019-01-25 KR KR1020207024432A patent/KR102748986B1/ko active Active
- 2019-01-25 TW TW108102958A patent/TW201940512A/zh unknown
- 2019-01-25 MX MX2020007882A patent/MX2020007882A/es unknown
- 2019-01-25 EP EP19707152.5A patent/EP3743441A1/en active Pending
- 2019-01-25 MY MYPI2020003848A patent/MY203898A/en unknown
- 2019-01-25 US US16/258,080 patent/US20190263934A1/en active Pending
- 2019-01-25 SG SG11202006905YA patent/SG11202006905YA/en unknown
- 2019-01-25 CN CN202411307275.XA patent/CN119350481A/zh active Pending
- 2019-01-25 AU AU2019212638A patent/AU2019212638B2/en active Active
- 2019-01-25 JP JP2020561607A patent/JP7399880B2/ja active Active
- 2019-01-25 IL IL318916A patent/IL318916A/en unknown
- 2019-01-25 CN CN201980015900.4A patent/CN111788221B/zh active Active
- 2019-01-25 CA CA3089602A patent/CA3089602A1/en active Pending
-
2020
- 2020-07-24 PH PH12020551134A patent/PH12020551134A1/en unknown
- 2020-07-24 MX MX2025009543A patent/MX2025009543A/es unknown
- 2020-08-20 CO CONC2020/0010269A patent/CO2020010269A2/es unknown
-
2023
- 2023-12-04 JP JP2023204313A patent/JP2024026255A/ja active Pending
-
2025
- 2025-06-26 AU AU2025204826A patent/AU2025204826A1/en active Pending
- 2025-10-24 JP JP2025179195A patent/JP2026021377A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024026255A5 (enExample) | ||
| IL276286B2 (en) | FC variants with improved binding to FCRN and extended half-life | |
| CN110382529B (zh) | 工程化的异源二聚体蛋白质 | |
| JP6435193B2 (ja) | 抗体を精製する方法 | |
| JP7566856B2 (ja) | 多重特異的抗体を調製するためのポリペプチドリンカー | |
| TWI585104B (zh) | 基於vl和vhh可變區衍生物的高親和力抗聚集抗體 | |
| CA2502904A1 (en) | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis | |
| JP2012515556A5 (enExample) | ||
| KR20120107140A (ko) | 면역글로불린 용액 정제 방법 | |
| CN113227134A (zh) | 抗体的Fc区变体 | |
| JPWO2019147973A5 (enExample) | ||
| CN111320693B (zh) | 抗EphA4抗体 | |
| CN111491951B (zh) | 通过疏水相互作用色谱法耗尽轻链错配的抗体变体 | |
| WO2021047559A1 (zh) | 一种断裂型内含肽、使用其的重组多肽的制备方法 | |
| CN106459191B (zh) | 选择具有修饰的FcRn相互作用的抗体的方法 | |
| JP2025098167A5 (enExample) | ||
| WO2022166728A1 (zh) | 双特异性抗体 | |
| JP2023526630A (ja) | Ｉｇ様分子の製造のための方法および手段 | |
| TW202204423A (zh) | 用於產生和純化多價免疫球蛋白單可變域的方法 | |
| JP2023508366A (ja) | 二重特異性ｆｃｙｒｉｉｉ×ｃｄ３０抗体構築体の製造方法 | |
| JP7796415B2 (ja) | エリスロポエチンポリペプチドを含む融合タンパク質 | |
| JPWO2021016571A5 (enExample) | ||
| JP2022512798A (ja) | 抗体ＦｃＲｎ結合の改変 | |
| JPWO2022166728A5 (enExample) | ||
| NZ767453B2 (en) | Fc variants with enhanced binding to fcrn and prolonged half-life |